echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The second oral COVID-19 drug approved by the FDA

    The second oral COVID-19 drug approved by the FDA

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The FDA approved the second oral drug for COVID-19 to respond to Omi Keron's challenge


    After Pfizer's COVID-19 oral drug Paxlovid was granted emergency use rights, the FDA approved the development of similar drugs by Merck & Co.


    The antiviral drug Molnupiravir, jointly developed by Merck and Ridgeback Biotherapy, effectively reduces the risk of hospitalization and death by approximately 30%


    Compared with Molnupiravir, Pfizer’s experimental oral drug Paxlovid can reduce the risk of hospitalization or death in high-risk COVID-19 patients by up to 89%


    Last month, the FDA advisory committee recommended the use of Molnupiravir as much as possible with a slight advantage


    The FDA on Thursday advised patients to use contraceptives during the medication and continue contraception within 4 days after the last medication


    The agency stated that the potential side effects of Molnupiravir include diarrhea, nausea and dizziness


    In a report submitted to the FDA expert panel, scientists from Merck said that they expect the drug to be effective against the Omicron variant virus, which contains mutations similar to other strains, but further testing is still needed


    Merck’s entire course of treatment includes 40 tablets, each with 200 mg, twice a day for 5 consecutive days


    At an expert meeting in November, Merck & Co.


    Health experts have always believed that the introduction of oral anti-coronavirus drugs will bring hope to the end of the epidemic, because it allows patients to receive treatment at home without the need for professional injections or droppers


    If these drugs can be delivered in time, they will help reduce the pressure on the medical system during the anticipated Omicron epidemic


    The US government has spent 5 billion yuan to purchase 10 million treatment courses of Paxlovid and has pledged to order approximately 3.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.